Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
WhichWayDoYouLook, When The Wolf is Stalking You?
OCAT now becomes the predator.
There is before phase 1, and after phase 1.
This makes all the difference.
Before phase 1, OCAT was the prey.
After phase 1, OCAT becomes the predator.
OCAT has mastered the IP for production and purification
of their RPE product. And now the world is their's to win.
A predator always stays downwind. And the market
analog to this is tights lips, and tight ships.
A good Captain, and for that matter a good Brit, knows
how to step on your throat, and how hard to dig in
the heel.
Is Secrecy ONVOs Big Flaw?
If a BP has to hand over their product to ONVO,
what safeguards, no matter how stringent, can be
given to safely protect information from leaking?
BP, and corporations in general, go to great extremes
to protect their information.
We only get to see the stories that burst out, like Sony.
The secrets we don't see are left to the imagination,
and the very rich.
ONVO may well have chosen poorly for their model of
bringing the customer to ONVO facilities. And instead
should have chosen a sub-contractor approach, where
they sell or contract, the machinery and the expertise to
the customer. This is less efficient, but the customer's
needs and wants are alway what it's about.
If your customers are control freaks, you still have to
give them what they want.
ONVOs model may look like a feeding frenzie for thieves
to BP. One corrupt guy could cause havoc.
ONVO can always change it and adapt if this is slightly true.
Something seems wrong. But maybe it's just early.
Lasers, Do you think this move is due
to the announcement of the full subscription
of the phase 2B for ix-DCM?
It's pretty close in time.
The Viva Las Vegas Liver Strips ARE Revolutionary
but the market doesn't seem to care.
There doesn't seem to be any big pharma interest.
It's been over a year since any meaningful rally.
This stock doesn't even bounce.
It's dead. It's completely dead.
18 million shorts have sucked the oxygen out
of its story.
I think the market has zero confidence in this CEO.
You can see their lab coats, even when they're not
wearing them. These guys were meant to be employees,
not leaders.
OCAT Makes Lucentis and Eylea OBSOLETE
And these 2 Drugs have combined sales of $6 Billion
And REGN has a $40 Billion Market Cap that OCAT
can now destroy with their technology.
This is not going to be pretty. But it's going to be fun.
Speaking about wet AMD.
PW: But what we're actually going to be able
to do is to catch these patients, before they
have to need to be treated with Lucentis or
Eylea.
PW: Our RPE Transplant Therapy takes care
of all three of these disorders.
Speaking about SMD, AMD, and MMD.
And since it is 'curative' it makes obsolete
all palliative treatment.
PW: For those of you who are familiar with
breakthrough stories in biotech or anywhere
else...the cells are actually going to be
given by retinal injection. Which is a technique
that's already used by physicians today. So
we're not asking them to do something they
don't know how to do.
Ted: This is a small company, but it controls its
destiny. We've got the manufacturing piece down.
We feel that we've got a lot of the foundation of
the fundamentals of the technology very well
mastered.
This is saying, 'we can go it alone' from the
technical side, the IP side
Roadshow 1.0
Lasers, you're right again here about OCAT.
The IP that OCAT uses to assay the RPE cells,
the technology that is required to purify or
ensure that the RPE cells are actually differentiated,
completely and fully is the key to STEM cell
technology.
Without this technology, no one, absolutely no one,
moves forward with a STEM cell therapy.
AND OCAT OWNS IT !!!
(until the patents run out, anyway)
If the market makers don't understand this,
it's their loss. And it's not surprising because
these guys don't understand algebra, much less
calculus.
So, be patient. And carry on.
It's interesting, and always over looked by the
dunderheads, that the most recent OCAT presentation
specifically focused on the IP chain, and the patents.
ONVO is not about printing organs
If you invested in ONVO for that,
you're a bit early.
ONVO is not really about 3D printing either.
ONVO is about drug testing for liver toxicity,
and their ex vive or poorly named product,
which only nerd geniuses can remember
how to spell or pronounce, or buy apparently.
The market only shorts ONVO, there is
absolutely no love for ONVO.
PW: I'm Making This Kind Of My Mission
Paul Wotton referring to the devastation people face
upon losing their eyesight. The sorrow that people
experience from losing something they once had,
their vision. Something you take for granted, if
you have it.
This company is where human virtue encounters
and mixes with business, capitalism, and simple
but exquisite, voluntary human cooperation.
If anyone produces wealth because of this company,
they will have earned it, and be deserving of it.
This company, litterally, produces, vision.
If there is anything devine, anything you can point
to, anything at all, that's actually devine, it's these
little syringes filled with Ocata's product that
repairs and restores a person's eyesight.
This is divinty, actual. Not a myth, not a story,
not an unreachable supernatural realm,
but reality, here and now, forever.
From coast to coast.
ONVO hasn't recovered from the March-April 2014
plunge. And it's coming up on a year now.
The elephant in the room is the enormous
short position against ONVO.
This is dead money in a bull market.
The broader market doesn't yet understand what
it means for the US to have an independent crude
oil supply. The US could potentially decouple from
the rest of the planet. And whoever we choose to
do business with, could potentially amount to a form
of economic grace from the kindly giant.
I think crude will sink to the cost of the lowest cost
producer. I was expecting vicious counter trend rallies,
but this has not happened, yet.
We've gone from a world where we were lead to
believe that the oil was about to be used up, to a
world that now has decades if not centuries of oil.
This is a fundamental change not yet recognized.
And as always, don't forget about the natural gas.
So if this is true, I expect the bull is not yet dead.
I don't want my money to be locked away in an
ONVO dead money zone. Or an oligarch short
sider zone.
ONVO needs to step it up, or the march of
technological innovation with pass them by.
All a competitor has to do is develop a way to
grow a complete liver independently. And the
speed at which things are moving this would
surprise me but not shock me.
With 20 Planned Sites For the US Phase2
and the 10 in Europe, OCAT will be able to
quickly transition from FDA trials, to for
profit patient therapy.
And with the small number of Retina Specialists,
of around 2,000, they could potentially hold
regional seminars, provide transportation and
lodging, and reach each specialist directly.
Perhaps an East coast, West coast, and a Denver,
or Park City seminar, once or twice, and you reach
every Retinal Surgeon in the country, if not the entire
world!
If there are only 2,000 in the US, there can't be that
many more in Europe or Asia.
Going it alone, will in the long run, be a brilliant strategy.
And the long run is getting shorter and shorter.
Todays throw away comment about being well
received by the FDA, is something to ponder.
Remember, this is an Orphan disease, and
an unmet medical need. Safety has been proven,
phase 2 will prove it again and again, and resolve
the dosage and immuno suppression issues.
Also remember, nothing negative was announced today.
Some things are still in the works, but are as yet
unknown or unannounced. The unknown and the arbitrary
has always been a hobgoblin for the weak-minded,
and those prone to fear.
It has always been a research biotech, and remains
a risky bet. But it has never looked better.
Look Out Below, 19 Million Shorts, Lackluster Management
New Short Data Tommorrow, with such heavy shorting the
company has to run as fast as it can, just to keep from
moving backwards
Lasers: $OCAT Paul Wotton has much to learn
imagine combining VCELs Lx-T technology with
OCATs, I think they are very close to a generalized
autologous technology where all medicine is
patient specific
remember how OCATs M cells were more effective
than those expanded from bone marrow
These are exciting times, I'm right behind you brother,
see you at cafe Luna! 3.14 !
Lasers, A Couple of Questions
After listening to the Minger presentation,
I wonder if I have this correct.
If you take a human embryo, remove the inside
genetic material, and replace it with the genetic
material taken from a human cell, from anywhere
in the body, any cell type
--- Is this what's known as therapeutic cloning?
(Is this possible with humans?)
And if it is, does this clone
produce a hESC or an iPSC ?
Thanks.
BTW, I knew there was controversy over Stem Cells,
but I didn't focus on what this was all about.
I'm just now beginning to look into this. And the Minger
presentation discusses some on this.
I got a little confused when he was talking about cow embryos.
I'll have to watch it again a pay closer attention this time.
Minger, Jan 2015
Does Any Other Company Have 42 Day Longevity?
for their liver test product?
- didn't think so
The Pop To 12.73 Was a Dramatic Foreshadowing
of what is to come. Many times reverse splits are
accompanied with up listing, or other actions. The
market didn't know for sure, but the power was
there waiting.
It's still there waiting.
Let's wait until Monday and see what Paul
has to say.
For PW, Keep Quiet and Carry On, Cheerios
OK, Cheerios is an American breakfast cereal.
But it makes a good laxative if you eat too much.
So that segues into a possible micro-biome
project for OCAT. It's all connected. It's all good.
Whatever's Going To Happen, IsJust About To Happen
With OCAT, that is.
OCAT Will Have Many More Employees in_The Future
Projecting the future trends with a straight edge is as effective
as analyzing a stock by comparing the low from the high.
Does it make any sense to hire the indians before the chief?
What would they do? Stand around until their chief was hired?
This new hire is being hired to take OCATs clinical capacity
from 4 in America, and 2 in Euope, to 20 and 10. This is
x5, or a quintupling of capacity.
And take RPE product inventory from thousands to millions.
This is OCATs plan for the Future.
This guy is being hired to implement the plan and hire his own
team. This is thoughtful management.
Ted: So the company, being the first, had to develop all the assays and all the testing that would be required to confirm that. The FDA has gone through, was comfortable, (IP, AS FAR AS THE EYE CAN IMAGINE) and as Eddy mentioned earlier, we've treated 38 patients safely. Again, safety, good IP, good protection, a lot of know-how that the rest of the market would have to try to catch up and find. Ultimately, once we confirm that they are RPE cells, we have methods to really support their further expansion, so that we can turn them into inventory for the treatment. This process oversimplifies, but sort of lays out what's currently about a 4 to 5 month process of the company and yields 1000 to 1200 doses of the therapy. All the trials that Eddy mentioned that we're going to be embarking on and supporting over the next two years will require about 200 doses. So as I mentioned earlier, this is a small company, but it controls its destiny. We've got the manufacturing piece down. We feel that we've got a lot of the foundation and the fundamentals of the technology very well mastered, and all we have to do now is do the work to show that we can make enough cells and enough doses to serve the entire market.
Roadshow 1.0
Lasers, The Contrarians Are Desperately Frightened By_Things_They_Don't_Understand
Post Phase 1,
Every PR from the company is verifiably positive.
With Science, it's all about the data. And OCATs data
is very, very positive. Efficacy is a major, major bonus,
during a safety trial.
So, now the frightened critics switch to the size of the data,
but this is determined by the FDA. Normal phase 1
trials are 20 to 80 people. It's purposefully kept small
to minimize potential damage.
http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=312.21
This is science. It's all very, very planned out.
And time tested as best we can.
To them it's all a gimmick, a trick.
Regenerative Medicine is a reality.
This is not 'going' to happen.
It has 'already' happened.
And it's genuinely wonderful.
Here is the story of a woman who discovered she could
see the detailed design of the carvings on her furniture,
with her OCAT injected eye.
If you really care about people, which I frankly don't,
I only own this stock to make money, but if you do care
about human suffering, or the alleviation of this suffering,
you cannot help but be touched by her story.
Dr. Stephen Schwartz on Charlie Rose show, 4/22/14
We've today transplanted a number of patients. These early stem cell studies seem safe. They seem astonishingly to be giving us a signal that there might be some restoration of vision. I wanted to share with you the first patient that we transplanted, a young lady who was a set designer and lost her vocation because of her blindness.
Cathy: When I was younger I played a lot of competitive tennis, and I think when I was like in my later teens, I started playing a little more poorly. It was seeing the lines or the ball not quite as precisely, and calling the lines and stuff was a little more difficult. I woke up one morning and I looked across my room and I have a piece of furniture there, that's kind of this large armoire and it has a lot of carved detail on it, and I actually had my head to the side and I opened the operated eye and I looked at it, and for the first time I could see the detail in it, that I hadn't been able to see from the distance I was lying down. After that I just got up and I started looking at everything around the house, and looked at the grass, I mean looking at everything with one eye and then the other eye, because you know they only operated on the one eye, and I could see it a lot better than I had before, and I thought, wow, maybe there is something here that will really be working you know. It was pretty exciting.
This is undeniably positive, FOR THIS WOMAN,
Living her life, on this good Earth.
For the rest of her life. Or perhaps until early next year.
The OCAT injected eye, is a younger, healthier
eye of the two.
And all she has to do is close an eye to bring the world
into complete focus.
Thank You Bob Lanza, THANK YOU.
I say BRAVO ! Let's go one to one with Novartis,
I'm down for that!
expanded, but incomplete, transcript
Dr. Stephen Schwartz on Charlie Rose show, 4/22/14
Dr. Schwartz: Well, as we have just discussed, gene therapy is now, you know, in late stage clinical trial development and showing remarkable safety, efficacy and durability, meaning it's working well within clinical trials guidelines, and it's poised in my opinion for approval. Stem cell, or regenerative medicine, is different. These studies are early. They hold great hope and promise, but are in the earliest stages of development. I would categorize them as highly experimental. Appropriately, the first stage of any new trial is a safety trial, or Phase I trial and that's what I'm going to talk to you about today. Our hypothesis centers on the idea that we could replace cells, so we can take a stem cell, which means that that cell is capable of becoming any cell type in the body. So we could take a stem cell, coax it, to use Eric's term, into becoming a retinal pigment epithelial cell, differentiate so to speak, and then take those differentiated cells and inject them into patients who are missing the retinal pigment epithelium with a hope of rescuing or even restoring vision. In this, our aim is to safely transplant these stem cell-derived retinal pigment epithelial cells and thereby replace the diseased or lost cells.
Eric Kandel: What's wonderful about these two people is, she's treating an individual gene in the pigment epithelium. He's replacing the whole population of pigment epithelium. It's really amazing.
Dr. Schwartz: MAYBE replacing…. We're trying to replace it. So for example, in macular degeneration, the retinal pigment epithelial cells are lost and we are trying to replace them, and we're using a strategy very similar to Jean and her team. We've taken human stem cells and we induce the differentiation, or we coax them into becoming the retinal pigment epithelial cells. Once they become the retinal pigment epithelial cells, we optimize them and harvest them at a time where they are most likely to succeed in transplantation, and then in the next line you can see what we're doing here is through surgery, we're transplanting them into the same space that Jean is using in her gene therapy trials to replace these cells. And once they are replaced, they rescue or restore vision by taking care of the photoreceptors that are adjacent to them.
Charlie Rose: Yeah, I don't understand how you coax them?
Dr. Schwartz: The truth is, it's a very surprisingly, astonishingly, straightforward method by which stem cells can be induced into certain cell types and it just turns out that retinal pigment epithelium are relatively low-hanging fruit in terms of being easy to induce the transformation to a terminally differentiated cell type. It's also important to realize that the retinal pigment epithelium are really attractive targets for stem cell therapy. Carla told us how integrated the retina is. The retinal pigment epithelium has no synaptic connections. It's protected by an immune privilege. It's inside the blood retinal barrier or blood brain barrier as Eric would say, and it's surgically accessible. So we can get to it surgically, relatively safely. It doesn't require synaptic connections. We can, in the laboratory, take the stem cells and turn them into essentially brand new, young, juvenile retinal pigment epithelium and give somebody a fresh layer of these cells that could take them, if they have macular degeneration and say they're 40, 50, 70 years old, for the duration.
We've today transplanted a number of patients. These early stem cell studies seem safe. They seem astonishingly to be giving us a signal that there might be some restoration of vision. I wanted to share with you the first patient that we transplanted, a young lady who was a set designer and lost her vocation because of her blindness.
Cathy: When I was younger I played a lot of competitive tennis, and I think when I was like in my later teens, I started playing a little more poorly. It was seeing the lines or the ball not quite as precisely, and calling the lines and stuff was a little more difficult. I woke up one morning and I looked across my room and I have a piece of furniture there, that's kind of this large armoire and it has a lot of carved detail on it, and I actually had my head to the side and I opened the operated eye and I looked at it, and for the first time I could see the detail in it, that I hadn't been able to see from the distance I was lying down. After that I just got up and I started looking at everything around the house, and looked at the grass, I mean looking at everything with one eye and then the other eye, because you know they only operated on the one eye, and I could see it a lot better than I had before, and I thought, wow, maybe there is something here that will really be working you know. It was pretty exciting.
Charlie Rose: How long will it be before you operate on the other eye?
Dr. Schwartz: Oh, a long time. We're very, very careful and step-wise and guided by you know the FDA appropriately, and by our own ethics committees at UCLA and at other universities, so only the worst eye for when we're not certain about safety, as opposed to say gene therapy, where now they're operating on the second eye of these kids. We have not. We're far from that, but we certainly have given this opportunity to a number of patients.
Eric Kandel: How many patients have you done so far?
Dr. Schwartz: Between 20 and 30, and they're actually the heroes. They're the people who willingly go into this with huge risks and they do it for….
Charlie Rose: What are the risks?
Dr. Schwartz: Well the risks in stem cell therapy and regenerative medicine are enormous. We're very careful about making certain that we've differentiated these cells into retinal pigment epithelium, but if we don't and we give them a straight stem cell, it could turn into anything, plus the body could reject. So we've been very lucky to have a heroic group of patients, essentially volunteer and put themselves in harm's way. It's really sort of miraculous what these people do for those who follow.
Eric: The encouraging thing is that so far things seem to be moving safely.
Rally, What Say You on The Short Data/Situation
I trust you, because you are the only one I've
noticed, who saw 2014, as the disaster that it was.
I'm googling around to try to learn about these heavily
shorted stocks. But I'm still standing in the middle
of the library not knowing which book to read.
Some think heavy short data is a good thing, because
of the potential for short covering spikes.
Some think it indicates the company doesn't know what
it's doing.
I think the shorts are holding this company down.
But I admit confusion.
1/15/2015 Shorts 18,783,290 AveDvol 793,995 Still Crushing
I don't understand why the price doesn't completely
tank on this. The offsetting buying must be enormous.
I do not understand this.
To me this looks like open interest on a futures contract.
But the price doesn't move, so how can anyone make
money on doing this? Why would you spend a 100
million to lock the price in a range, to make a smaller
amount on options?
OCAT Restores Your Vision, By Restoring Your Retina,
More properly, restoring your Pigment Epithelium, the
single cell thick bottom layer of your retina, containing
the nurse cells that maintain the ten cell thick retina.
"There are literally dozens of retinal degenerative diseases and these diseases are usually caused by the loss of the RPE cells."
-Dr. Robert Lanza
This is a revolutional medical product, that will be discussed
for a thousand years, in medical schools and business
courses. It changes medicine, forever.
Dr. Lanza
Rally You're Right, Any Critical Thinking AndYou'reA_stealthShorter
This board doesn't address the 19 Million Shorts either.
It just doesn't exist I guess if you bought in at 2 dollars.
The 5 to 6 resistance area can crack and vanish in a
few micro-seconds if this company doesn't get control
back of the narrative.
If they are making deals with big P companies who demand
confidential agreements, they need to wake up a smell
the coffee here, and understand they are being punked.
Feb 7, my fingers and toes are crossed. Nice pop yesterday.
It's not getting cheaper, 6$ is the bottom
for now. All the moving averages are 6 -something.
So it's been going sideways for quite a while now.
I was hoping it would get cheaper.
The fact that all trial participants requested their
other eye be injected is very good anecdotal,
(non-scientific) evidence of the value of the RPE
therapy.
People want this. And in a way, that's all that matters
when you're selling something.
Thanks for the timeline info.
I'm very invested in this company.
I like the concept and can easily
imagine the implications for the
future.
The 19 Zillion shorts position
completely bewilders me. I
don't know if this is an algorithm,
or a database entry, or an evil genius.
At least I'm aware of my confusion.
Yeah, Except the Share Price ISN'T Going Down
Please Crater This Thing, PLEASE!
4.95 Is The Low. GO FOR IT!
Holding Steady at 6, on no news, shows strength,
not weakness.
No News is Good News, I'm Guessing
We live in a context where, if it bleeds, it leads.
People are building bunkers, because of this fear,
everything's a disaster, mentality. It's pandemic.
If something has gone wrong, I can't see how they
would risk not disclosing it immediately.
I think it's very possible that expectations were EXCEEDED.
And the quiet time is to prepare for whirlwind
that's coming. It's not PWs first rodeo.
This is a cure for blindness. That's huge.
This is a new branch of medicine. That's huge-ER.
We'll see. My time frame is before year end.
I'm already all in, if there's a plunge, I'll buy as
much as I can.
exVive3Ds Only Live 6 weeks, Plenty_of_Time_has_Passed
for a batch to have been sold and money to have
been collected.
If the next 10Q continues with the under promise,
under deliver strategy, I don't see how the share
price can do anything except crumble.
19 Million Shorts for 80 Million Shares Outstanding,
this is the overbearing context. When you take out
the institutional and insider shares, the shorts are
magnified even more intensely.
10 Feb will mark 2, six week cycles for the little
livers, let's hope we hear something, at least.
OCAT Does Not Inject ESCs Embryonic Stem Cells
medtronic article is completely wrong
Everywhere below where you see 'ESC' Should be
replaced by RPE.
This is the entire genius of OCATs technology.
The RPE Cells are differentiated, (created) OUTSIDE
the body, BEFORE injection. No ESCs are injected.
You cannot call what OCAT is injecting an ESC,
because the ESCs have been made into RPE
cells, and are now something else entirely.
It would be like calling a brick sidewalk, a cement
sidewalk, because the bricks are made from cement.
The bricks are made from cement, and are now bricks,
not cement.
It's the same for OCATs RPE cells. They're not ESCs.
They are DERIVED from ESCs, and they are now RPE
cells, identical to the cells present in your eyes.
This is a very sloppy article. And I doubt if it's innocent.
Listen again to Dr. Anglade
Roadshow 1.0
OCAT is_a Research Biotech, which have Certain Characteristics
Research Biotech Characteristics (some)
-No Revenue
-No Product Ready for the Market
-Share Price does not Represent Anything Real
To critique a research biotech for any of these
characteristics, is to not understand the very
purpose and nature of Research Biotech Companies.
A Research Biotech does not exist to generate Revenue.
A (start-up)Research Biotech doesn't have a marketable Product.
A Research Biotech's share price is completely Subjective.
Research Biotech Companies are a Brilliant Feature of
Modern American Capitalism. Thomas Edison invented it.
Now Positively, A Research Biotech solely exists
FOR RESEARCH, IT'S ONLY ABOUT THE RESEARCH !
Secondarily, the company must stay in business,
any way it can, TO CONTINUE ITS RESEARCH.
Share price is completely irrelevant, and subordinate
to these two things.
OCAT's Research is Proceeding Brilliantly.
Now OCAT is EVALUATING its Research.
This is done in the context of FDA Phased Trials.
Phase 1/2 is completed, PROVING the product is
safe to begin the next phase, pivotal phase 2B.
THIS IS MONUMENTALLY IMPORTANT.
OCATs RPE Cell Therapy is the FIRST Company to begin
the journey through the FDA process.
Therapeutic Cell Therapy is being forecast by GE to
grow to a Trillion Dollar Marketplace,heh!, over the next
decade through 2025. GE is in the top twenty market
cap companies in America, usually in the top ten.
And they sell high tech lab equipment, and provide
medical and patient services. They are major players
who are not 'guessing', they're adding up their order
books, and making enlightened forecasts.
I don't think anything can stop this company, unless
the management or the regulators intentionally bury it,
or intentionally drive it into a ditch.
We live in an age where common men live entire lives
without a meaningful wage raise. It wouldn't surprise
me if this never amounts to anything, share price-wise,
because lots of little people own this stock.
So, strongly against this company, we have conspiracy
and class-envy. And I don't 'know' that these things
aren't real.
One more week of trading for Jan 2015,
and 1/12 of 2015 is history, over, done.
And ONVO continues sideways, completely
dead money.
19 Million Shorts may have something to do
with it, record all time high shorts.
Nothing from the company whatsoever.
Company Silence, Record High shorts = Dead Money
as far as the eye can see. The trend precedes 2015,
and nothing has changed in 2015. Sideways, dead money.
I've already sold a third, that helped for a while, but
it's now wearing off fast.
19 Million Shorts, Sideways Chart, Company Silence,
This recipe and these ingredients make a bitter
dead money stew.
Convince me otherwise, please.
GE_Healthcare_is_Predicting_a 1 Trillion Dollar Marketplace by_2025
for Regenerative Medical Therapy.
"Could cell therapy be a trillion dollar industry by 2025? GE thinks so..." link below
(I love this story. A TRILLION Dollar Market, heh!)
GE is one of the most successful organizations in
human history. And for GE Healthcare to make such a bold
prediction is hugely significant. This cannot be casually
dismissed, not validly.
A Trillion Dollars in ten years, is a hundred billion
growth each year.
OCAT has the FIRST regenerative therapy that is
FDA Approved!
Being first through the FDA gauntlet is nothing to
be dismissed lightly. This represents two things.
Firstly, it highlights the ENORMOUS lead that OCAT
enjoys over EVERYONE !
Second, it places OCAT in the position of the
Marketplace Gold Standard Bearer. OCAT has
worked with the FDA to invent the regulatory
protocols that all future cell therapy will be judged
against.
This will be rewarded in the marketplace with a
market cap not yet imagined, and right now too
scary to contemplate.
Phase 1 confirms everything going on here.
Complete safety, with indications of efficacy,
is hugely significant. This cannot be casually
dimissed, not validly.
The FDAs own guidelines, state that phase 1 trials
vary from 20 to 80 patients. OCATs 40 patient
phase 1 trial is completely reasonable, and
is more or less typical in size.
http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=312.21
There's more work to do, but there's every reason,
every indication, to look positively upon OCAT.
GE Healthcare looks positively upon the entire ReGen
marketplace, of which OCAT is the unchallenged
leader.
OCAT has the FIRST regenerative therapy that is FDA Approved!
http://www.signalsblog.ca/cell-therapy-commercialization-a-view-from-ge-healthcare-on-immunotherapy/
Unfortunately, Gaps Are Usually Filled, 5.50isTheGap
Gaps are like a giant magnet.
Lasers, is OCAT eligible for Orphan Status?
BTW, great opinions, great ideas, thank you.
I've been reading about the tax breaks and
other benefits of attaining orphan drug status,
is Ocata's RPE therapy eligible for anything like this?
It would seem like Stargarts disease fits the notion
of a devastating disease affecting a small population.
OCAT's IP portfolio is going to generate quite a chunk
of GE's 25T ReGen marketplace. This is a very
interesting little company.
OCAT Threw_a_CuringBlindnessParty And_Nobody_Came
Still, from stem cell discovery in 1998, to RPE Therapy in 2014,
it's lightspeed fast when you think rationally about it.
It's less than 20 years.
Apparently it's just not worth anything.
HopaJ is right, OCAT deservesToBeDriven DownTo Atleast_2$
Such a shame. It's all a scam, scam, scam.
The Gap's at 5.50, Just Get it OverWith.
Tommorrow We Uplist, And We Find out Everything.
I expect the underwriters didn't want to do anything
until we were at our destination market, Nasdaq or
maybe the Amex.
A slight change perhaps, but no biggie.
Next year at this time we'll be moving to the ND100,
yeah, you heard me!
OCAT Phase2 TrialsWill Conclusively Prove Efficacy AndEndEarly
(This is half prediction and half asking what if?)
Remember,
OCATs therapy is not a drug, it's a tissue transplant.
They transplant cells identical to the existing tissue
in the eye already.
So these FDA trials won't have the same characteristics
as a drug trial.
A simple eye chart is all the testing required to demonstrate
efficacy. But with the eye, there exists ultra-high resolution
imaging technology that can peer into the eye and practically
see on the cellular level. This is another reason the eye was
chosen as a first candidate.
Markets look forward, and with OCAT so far, all the surprises
have been good surprises. Like 100% safety, Cowboy 20/40,
a surprisingly great new management team, surprising that
the lawsuits all cleared up finally.
Everything that could have been worse, wasn't.
Everything got better last year.
This is the Worlds first FDA Approved,(partially thru phase1),
Regenerative Medical Therapy.
It is also a risky biotech stock.
Thanks, Lasers, I only get 1 post a day here, I can't respond
back and forth. GLTmost
Roadshow 1.0